內地調整新冠診療藥物方案 新納入安巴韋單抗/羅米司韋單抗注射液等
國家衛健委醫政醫管局向各省、自治區、直轄市及新疆生產建設兵團衛生健康委、中醫藥管理局發出通知,調整新冠診療方案。通知指出,當前,新型冠狀病毒肺炎疫情仍在世界範圍內持續流行,Omicron毒株已取代Delta毒株成爲主要流行株,新型冠狀病毒肺炎患者臨牀表現呈現新的特點,且針對新型冠狀病毒肺炎治療的新藥物已相繼上市,治療經驗和治療手段進一步豐富。
爲進一步科學、規範做好新型冠狀病毒肺炎診療工作,組織專家對《新型冠狀病毒肺炎診療方案(試行第八版修訂版)》相關內容進行修訂,形成了《新型冠狀病毒肺炎診療方案(試行第九版)》。
當局亦批準新的抗新冠病毒藥物寫入診療方案。包括第一款是利託那韋片(Paxlovid),適用人羣爲發病5天以內的輕型和普通型且伴有進展爲重型高風險因素的成人和青少年(12-17歲);第二款是的安巴韋單抗/羅米司韋單抗注射液,聯合用於治療輕型和普通型且伴有進展爲重型高風險因素的成人和青少年(12-17歲)。
據騰盛博藥(02137.HK)去年12月曾公佈,國家藥品監督管理局批準騰盛華創醫藥技術(北京)新冠病毒中和抗體聯合治療藥物安巴韋單抗注射液(BRII-196)及羅米司韋單抗注射液(BRII-198)註冊申請。這是內地首家獲批的自主知識產權新冠病毒中和抗體聯合治療藥物。
騰盛博藥今早股價曾高見11.4元一度抽升36%,最新報9.63元升16.5%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.